John F Elenewski, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 407 Saint Andrews Place, Manalapan, NJ 07726 Phone: 609-947-3970 Fax: 609-947-3970 |
News Archive
OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, presented today at the AABB Annual Meeting & CTTXPO 2010, in Baltimore, Maryland, results showing that hemoglobin (Hb) measurements obtained by its NBM 200, a non-invasive Hb measurement system for anemia screening, showed accurate performance compared with invasive point of care (POC) devices.
Measuring a hormone in the blood can help doctors greatly reduce the number of days pneumonia patients have to take antibiotics to cure their infection, according to a study to be presented at the American Thoracic Society International Conference.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.
Results of a new phase 2 clinical trial using technology developed at Northwestern Medicine show it is possible to induce immune tolerance to gluten in individuals with celiac disease. The findings may pave the way for treated celiac patients to eventually tolerate gluten in their diet.
A new form of congenital muscular dystrophy has been discovered which is caused by mutations in a previously un-linked gene.
› Verified 3 days ago